Atlas Trials

Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM

Clinical trial NCT05118776 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05118776
Sponsor
Ascletis Pharmaceuticals Co., Ltd.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Recurrent Glioblastoma
Start date
2022-01-21
Primary completion
2025-06-01
Enrollment
136

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.